Key Market Indicator:
F&G: 26
24.640,75 NASDAQ · 47.233,00 DOW · 6.677,76 S&P · 4.131,39 Gold · 63,64 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
© Globe Newswire
22.09.2025
ISIN: LU2458332611

Alvotech SA
ALVO

LISTED

ICE
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
News Preview
REYKJAVIK, ICELAND (September 22, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion recommending appro...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: LU2458332611

Alvotech SA
ALVO

LISTED

ICE
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
News Preview
REYKJAVIK, Iceland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion rec...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
22.09.2025
ISIN: US45408X3089

IGC Pharma, Inc
IGC

LISTED

XASE
IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial
News Preview
POTOMAC, MD / ACCESS Newswire / September 22, 2025 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer's disease, today announced it has reached a key enrollment milestone of 50% for its ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation in Alzheimer'...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar

USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© ACCESSWIRE
22.09.2025
ISIN: US5845073056

Medical Care Technologies Inc.
MDCE

LISTED

OTC
Medical Care Technologies Inc. Introduces AI Breakthrough for Squamous Cell Carcinoma Detection
News Preview
MESA, ARIZONA / ACCESS Newswire / September 22, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced a significant innovation in dermatological AI: a platform capable of detecting squamous cell carcinoma (SCC), the second most common skin cancer and a condition responsible for more than 15,000 deaths annually in the United States a...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
22.09.2025
ISIN: LU2458332611

Alvotech SA
ALVO

LISTED

ICE
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
News Preview
REYKJAVIK, ICELAND and LONDON, UK (September 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital,...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: LU2458332611

Alvotech SA
ALVO

LISTED

ICE
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
News Preview
REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty,...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US89377M1099

Transmedics Group Inc
TMDX

LISTED

NASDAQ
TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy
News Preview
Modern, purpose-built Mercedez-Benz V-Class fleet to be deployed across four National OCS Program ("NOP") hubs in Italy to support utilization of TransMedics' Organ Care System ("OCS") perfusion technology and increase donor organ utilization for patients in need TransMedics President and Chief Executive Officer, Waleed Hassanein, M.D., to discu...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: US89377M1099

Transmedics Group Inc
TMDX

LISTED

NASDAQ
TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy
News Preview
Modern, purpose-built Mercedez-Benz V-Class fleet to be deployed across four National OCS Program ("NOP") hubs in Italy to support utilization of TransMedics' Organ Care System ("OCS") perfusion technology and increase donor organ utilization for patients in need TransMedics President and Chief Executive Officer, Waleed Hassanein, M.D., to discu...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
22.09.2025
ISIN: US60458C1045

Mira Pharmaceuticals Inc
MIRA

LISTED

NASDAQ
MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
News Preview
Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with no severe or clinically significant adverse effects observed. The drug showed rapid and predictable absorption, a favorable duration of action supporting once-daily dosing, and no CNS side effects typically seen with k...
Themefolio
Profiler
Peergroup
© EQS Newswire
22.09.2025
ISIN: CH0038389992

BB Biotech AG
BION

LISTED

SIX
BB Biotech to be included in the SPI ESG Index
News Preview
Media release as at September 22, 2025 BB Biotech to be included in the SPI ESG Index BB Biotech AG announces that it will be included in the SPI ESG Index of the SIX Swiss Exchange as of today, September 22, 2025. This highlights the investment company’s long-standing commitment to responsible investing and sustainable corporate governance. Dr.......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.09.2025
ISIN: CH1110760852

PolyPeptide Group AG
PPGN

LISTED

SIX
PolyPeptide Group achieves significant milestone in Malmö expansion project
News Preview
PolyPeptide Group / Key word(s): Expansion PolyPeptide Group achieves significant milestone in Malmö expansion project 22.09.2025 / 07:00 CET/CEST Media Release   PolyPeptide Group achieves significant milestone in Malmö expansion project Baar, 22 September 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized, globa......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.09.2025
ISIN: CH0038389992

BB Biotech AG
BION

LISTED

SIX
BB Biotech wird in den SPI ESG Index aufgenommen
News Preview
Medienmitteilung vom 22. September 2025 BB Biotech wird in den SPI ESG Index aufgenommen Die BB Biotech AG gibt bekannt, dass sie per heute, 22. September 2025 in den SPI ESG Index der SIX Swiss Exchange aufgenommen wird. Damit wird das langjährige Engagement der Investmentgesellschaft für verantwortungsbewusstes Investieren und nachhaltige Unter......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
22.09.2025
ISIN: FR0012127173

OSE Immunotherapeutics SA
OSE

LISTED

EURONEXT
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting
News Preview
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: FR0000120578

Sanofi SA
SAN

LISTED

EURONEXT
Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
News Preview
Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: FR0010259150

Ipsen SA
IPN

LISTED

EURONEXT
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
News Preview
PARIS, FRANCE, 22 September 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first aesthetic data (n=183) for glabellar lines with internally developed IPN10200, following Stage 1 of the multi-stage, ongoing Phase II LANTIC trial. Patients treated with IPN10200 showed a statistically significant improvement in response at Week 4 vs plac...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: CH0363463438

Idorsia Ltd
IDIA

LISTED

SIX
Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China
News Preview
Allschwil, Switzerland – September 22, 2025Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has launched QUVIVIQ® (daridorexant) in China. QUVIVIQ, Idorsia’s dual orexin receptor antagonist, is indicated for the treatment of adult patients with insomnia characterized by difficulty falling asleep and/or...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: CH0012032048

Roche Holding AG
ROG

LISTED

SIX
Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer
News Preview
Basel, 22 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III evERA study evaluating investigational giredestrant in combination with everolimus in people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer p...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: FR0000120578

Sanofi SA
SAN

LISTED

EURONEXT
Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
News Preview
Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
ISIN: US75886F1075

Regeneron Pharmaceuticals Inc
REGN

LISTED

NASDAQ
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
News Preview
Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
ISIN: CNE100003F19

Wuxi Apptec Co., Ltd.
2359

LISTED

HKSE
WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends
News Preview
SHANGHAI, Sept. 21, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, implemented its first interim dividend plan, distributing a total of RMB1.03 billion in cash...
Themefolio
Profiler
Peergroup
© BusinessWire
21.09.2025
ISIN: US8753722037

Tandem Diabetes Care Inc
TNDM

LISTED

NASDAQ
TNDM Investors Have Opportunity to Join Tandem Diabetes Care, Inc. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tandem Diabetes Care, Inc. (“Tandem” or “the Company”) (NASDAQ: TNDM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or fail...
Themefolio
Profiler
Peergroup
© BusinessWire
21.09.2025
ISIN: US4718712023

Jasper Therapeutics, Inc.
JSPR

LISTED

NASDAQ
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission....
Themefolio
Profiler
Peergroup
© PR Newswire
21.09.2025
ISIN: US5165441032

Lantheus Holdings Inc
LNTH

LISTED

NASDAQ
LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 21, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025, both dates i...
Themefolio
Profiler
Peergroup
© PR Newswire
21.09.2025
ISIN: US53216B1044

LifeMD, Inc.
LFMD

LISTED

NASDAQ
LFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
News Preview
NEW YORK, Sept. 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD) between May 7, 2025 and August 5, 2025, both dates inclusive (the "Cla...
Themefolio
Profiler
Peergroup
© PR Newswire
21.09.2025
ISIN: US8051111016

Savara Inc
SVRA

LISTED

NASDAQ
SVRA Investors have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 20...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.09.2025
ISIN: IL0006290147

Teva Pharmaceutical Industries Ltd
TEVA

LISTED

TLV
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
News Preview
PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of data from a real-world survey of patients taking AUSTEDO XR® (deutetrabenazine) extended-release tablets. Patients taking AUSTEDO XR rep...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.09.2025
ISIN: IL0006290147

Teva Pharmaceutical Industries Ltd
TEVA

LISTED

TLV
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
News Preview
PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of 10 posters from its innovative schizophrenia medicines portfolio, including long-term safety data from the completed SOLARIS Phase 3 tri...
Themefolio
Profiler
Peergroup
© BusinessWire
20.09.2025
ISIN: US4718712023

Jasper Therapeutics, Inc.
JSPR

LISTED

NASDAQ
Rosen Law Firm Urges Jasper Therapeutics, Inc. (NASDAQ: JSPR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR), between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”). Jasper is a clinical-stage biotechnology company. For more information...
Themefolio
Profiler
Peergroup
© BusinessWire
20.09.2025
ISIN: US76029N1063

Replimune Group Inc
REPL

LISTED

NASDAQ
REPL Deadline: Rosen Law Firm Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 22 Deadline in Securities Class Action First Filed by the Firm – REPL
News Preview
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If yo...
Themefolio
Profiler
Peergroup
© PR Newswire
20.09.2025
ISIN: US76029N1063

Replimune Group Inc
REPL

LISTED

NASDAQ
Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman
News Preview
REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline SAN FRANCISCO, Sept. 20, 2025 On September 18, 2025, investors in Replimune Group, Inc. (NASDAQ: REPL) saw the price of their shares crater about...
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

CSE
Steht die Aktie vor einer Neubewertung? Nanopartikel-Meilenstein ebnet Weg zu präklinischen Studien
News Preview
EQS-Media / 20.09.2025 / 15:40 CET/CEST Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass “Dalton Pharma Services” (“Dalton”) seine Aktivitäten zur Herstellung der proprietären Nanopartikelformulierung von Onco, auch als “PEO-b-PBz-CL” Poly(ethylenoxid)-Block-Poly(-benzylcarb......
Themefolio
Profiler
Peergroup
© PR Newswire
20.09.2025
ISIN: US78349D1072

Rxsight Inc
RXST

LISTED

NASDAQ
RXST Deadline: RXST Investors with Losses in Excess of $100K Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 20, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between May 7, 2024 and July 8, 2025, both dates inclusive (the "Clas...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.09.2025
ISIN: US12529R1077

C4 Therapeutics Inc
CCCC

LISTED

NASDAQ
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
News Preview
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma Patient Population...
Themefolio
Profiler
Peergroup
© EQS Newswire
20.09.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

CSE
Onco-Innovations beginnt gemeinsam mit “Dalton Pharma” mit der Herstellung von Nanopartikelformulierungen für präklinische Tierstudien
News Preview
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich bekannt zu geben, dass “Dalton Pharma Services” (“Dalton”) seine Aktivitäten zur Herstellung der proprietären Nanopartikelformulierung von Onco, auch als “PEO-b-PBz-CL” Poly(ethylenoxid)-Block-Poly(-benzylcarboxylat -caprolacton) bezeichnet, begonnen hat......
Themefolio
Profiler
Peergroup
© PR Newswire
20.09.2025
ISIN: US5165441032

Lantheus Holdings Inc
LNTH

LISTED

NASDAQ
Did you lose money in LNTH? Shareholders Who Incurred Significant Losses in Lantheus Holdings, Inc. Should Contact Robbins LLP for Information
News Preview
SAN DIEGO, Sept. 19, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Lantheus Holdings, Inc. (NASAQ: LNTH) securities between February 26, 2025 and August 5, 2025. Lantheus is a global company that develops, manufactures, sells, and distribu...
Themefolio
Profiler
Peergroup
© PR Newswire
20.09.2025
ISIN: US02157Q1094

Alto Neuroscience, Inc.
ANRO

LISTED

NYSE
Alto Neuroscience, Inc. Class Action Notice: ANRO Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Securities Lawsuit
News Preview
SAN DIEGO, Sept. 19, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired (a) Alto Neuroscience, Inc. (NYSE: ANRO) common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering ("IPO") conduc...
Themefolio
Profiler
Peergroup
© Newsfile
20.09.2025
ISIN: CA74141E1043

PreveCeutical Medical Inc.
PREV

LISTED

CSE
PreveCeutical Announces Mailing and Filing of Annual General and Special Meeting Materials in Connection with a Proposed Arrangement with BioGene Therapeutics
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 19, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that further to its News Release of September 4, 2025, it has filed with the applicable Canadian securities regulatory authorities the management information ci...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US58933Y1055

Merck & Co Inc
MRK

LISTED

NYSE
FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for KEYTRUDA® (pembrolizumab). Berahyaluronidas...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US4781601046

Johnson & Johnson
JNJ

LISTED

NYSE
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
News Preview
TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA® achieved significant rates of clinical remission and endoscopic improvement versus placebo at Week 12 with a subcutaneous induction regimen, consistent with IV induction Johnson...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US1266501006

CVS Health Corp
CVS

LISTED

NYSE
CVS Pharmacy celebrates reopening of Pacific Palisades store damaged by devastating wildfires
News Preview
The Swarthmore Avenue CVS Pharmacy is the first community pharmacy to reopen in the neighborhood, increasing access to health and wellness essentials WOONSOCKET, R.I., Sept. 19, 2025 /PRNewswire/ -- Today, leaders from CVS Health® (NYSE: CVS) were joined by state and local representatives to celebrate the recently reopened Pacific Palisades CVS P...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.09.2025
ISIN: CA98421R1055

XPhyto Therapeutics Corp.
XPHY

LISTED

CSE
BioNxt Solutions Announces Closing of Shares for Debt Settlement
News Preview
VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that, further to its news release of September 12, 2025, it has closed its debt settlement with an arm's length creditor (the "Creditor") related to an aggrega...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: CA7615161030

Revive Therapeutics Ltd.
RVV

LISTED

CSE
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
News Preview
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed a second tranche of its previously announced private placement (see...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: CA01559R1038

Algernon Pharmaceuticals Inc.
AGN

LISTED

CSE
Algernon Announces Preferred Share Class Approved at Annual and Special Meeting
News Preview
VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces the voting results at its annual and special meeting of shareholders held earlier today (the "Meeting") including an ordinary resolution (t...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US4330001060

Hims & Hers Health Inc
HIMS

LISTED

NYSE
Berger Montague Investigates Hims & Hers Health Inc. (NYSE: HIMS) Board of Directors for Potential Breaches of Fiduciary Duties
News Preview
PHILADELPHIA, Sept. 19, 2025 /PRNewswire/ -- Berger Montague, a national securities litigation law firm, advises shareholders of Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) about an investigation into Hims & Hers' Board of Directors for potential breaches of fiduciary duties to the Company and its shareholder...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US7133171055

PepGen Inc
PEPG

LISTED

NASDAQ
Kuehn Law Encourages Investors of PepGen Inc. to Contact Law Firm
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of PepGen Inc. (NASDAQ: PEPG) breached their fiduciary duties to shareholders.  Ac...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US90400D1081

Ultragenyx Pharmaceutical Inc
RARE

LISTED

NASDAQ
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
NOVATO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,561 restricted stock units of the company’s common stock to 17 newly hired non-executive...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: GB00BMVP7Y09

Royalty Pharma PLC
RPRX

LISTED

NASDAQ
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
News Preview
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein’s 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US55287L1017

MBX Biosciences, Inc.
MBX

LISTED

NASDAQ
MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22
News Preview
CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will provide topline results from its Phase 2 clinical trial...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: CA71719L1067

Pharmala Biotech Holdings Inc.
MDMA

LISTED

CSE
PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus
News Preview
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has filed an amended and restated preliminary sh...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: FR0004163111

Genfit SA
GNFT

LISTED

EURONEXT
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 19, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its decision to discontinue its VS-01 program in ACLF (Acute-on-Chronic Liver...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US2521311074

Dexcom Inc
DXCM

LISTED

NASDAQ
Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders. Ac...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US78349D1072

Rxsight Inc
RXST

LISTED

NASDAQ
Deadline Soon: RxSight, Inc. (RXST) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
News Preview
The Law Offices of Frank R. Cruz reminds investors of the upcoming September 22, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) securities between May 7, 2024 and July 8, 2025, inclusive (the “Class Per...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ISIN: US88165K1016

Tevogen Bio Holdings Inc.
TVGN

LISTED

NASDAQ
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
News Preview
WARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its gratitude to the U.S. Department of Health and Human Services (HHS), Secretary Robert F. Kennedy, Jr., and the Trump Administration for convening two Long COVID roundtables focused on patient experiences and rese...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US88023B1035

Tempus AI, Inc.
TEM

LISTED

NASDAQ
Kuehn Law Encourages Investors of Tempus AI, Inc. to Contact Law Firm
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Tempus AI, Inc. (NASDAQ: TEM) breached their fiduciary duties to shareholders. ...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.09.2025
ISIN: CA98421R1055

XPhyto Therapeutics Corp.
XPHY

LISTED

CSE
Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals
News Preview
VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that Terry Lynch, CEO of Power Metallic Mines Inc. (TSX-V: PNPN), will continue his role as a capital markets advisor to the Company. Mr. Lynch brings decades of early-s...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US81684M1045

Semler Scientific Inc
SMLR

LISTED

NASDAQ
SMLR Investors Have Opportunity to Lead Semler Scientific, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Semler Scientific, Inc. (NASDAQ: SMLR) between March 10, 2021 and April 15, 2025, both dates inclu...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US23282W6057

Cytokinetics Inc
CYTK

LISTED

NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Cytokinetics, Incorporated (CYTK) Investors To Inquire About Securities Fraud Class Action
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusi...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2025
ISIN: US2825591033

89Bio, Inc.
ETNB

LISTED

NASDAQ
89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB
News Preview
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 89bio, Inc. (NasdaqGM: ETNB) to Roche Holding AG (OTC: RHHBY). Under the terms of the proposed transaction, shareholders of 89bio will receive $14.50 per share in cash at closing, plus a non-...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
ISIN: US8292141053

Simulations Plus Inc
SLP

LISTED

NASDAQ
Rosen Law Firm Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
News Preview
NEW YORK, Sept. 19, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public....
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.09.2025
ISIN: CA68237C1059

Onco-Innovations Limited
ONCO

LISTED

CSE
Onco-Innovations Commences Activities to Manufacture Nanoparticle Formulation with Dalton Pharma to Supply Preclinical Animal Studies
News Preview
VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / Onco-Innovations Limited (CBOE CA:ONCO )(OTCQB:ONNVF )(Frankfurt:W1H) (WKN: A3EKSZ ) (" Onco " or the " Company ") is pleased to announce that Dalton Pharma Services ("Dalton") has commenced activities to manufacture Onco's proprietary nanoparticle formulation, als...
Themefolio
Profiler
Peergroup

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

© 2025 Select Sector SPDRs

* * *

More Sector related Investment Ideas
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Friday, 14.11.2025, Calendar Week 46, 318th day of the year, 47 days remaining until EoY.